AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion

The deal is AbbVie’s latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic competition.

Previous post McDonald’s to open first CosMc’s spinoff restaurant this week
Next post : Bristol Myers Squibb raises dividend by 5.3%